This is a multi-site, prospective, non-randomized phase 2 study evaluating neoadjuvant botensilimab in combination with balstilimab for patients with microsate…

Early Rectal CancerStage I Rectal CancerMicrosatellite Stable Rectal Carcinoma

~Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07735624

Phase 2

A Phase II Study of Neoadjuvant Botensilimab and Balstilimab Immunotherapy for Mismatch Repair Proficient Rectal Adenocarcinoma

The purpose of this study is to find out whether the combination of botensilimab and balstilimab (BOT/BAL) is a safe and effective treatment that causes few or…

Microsatellite Stable Rectal CarcinomaLocally Advanced Rectal Adenocarcinoma

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06843434